-
Guggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS)
Source: Buzz FX / 18 Jan 2025 10:16:17 America/New_York
Guggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS) Written by MarketBeat January 18, 2025 Share Link copied to clipboard. Keros Therapeutics ( NASDAQ:KROS - Get Free Report ) 's stock had its "neutral" rating reiter
Read more...